Literature DB >> 31554932

The regulation of hepatic fatty acid synthesis and partitioning: the effect of nutritional state.

Leanne Hodson1,2, Pippa J Gunn3,4.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) is an increasing global public health burden. NAFLD is strongly associated with type 2 diabetes mellitus, obesity and cardiovascular disease and begins with intrahepatic triacylglycerol accumulation. Under healthy conditions, the liver regulates lipid metabolism to meet systemic energy needs in the fed and fasted states. The processes of fatty acid uptake, fatty acid synthesis and the intracellular partitioning of fatty acids into storage, oxidation and secretion pathways are tightly regulated. When one or more of these processes becomes dysregulated, excess lipid accumulation can occur. Although genetic and environmental factors have been implicated in the development of NAFLD, it remains unclear why an imbalance in these pathways begins. The regulation of fatty acid partitioning occurs at several points, including during triacylglycerol synthesis, lipid droplet formation and lipolysis. These processes are influenced by enzyme function, intake of dietary fats and sugars and whole-body metabolism, and are further affected by the presence of obesity or insulin resistance. Insight into how the liver controls fatty acid metabolism in health and how these processes might be affected in disease would offer the potential for new therapeutic treatments for NAFLD to be developed.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31554932     DOI: 10.1038/s41574-019-0256-9

Source DB:  PubMed          Journal:  Nat Rev Endocrinol        ISSN: 1759-5029            Impact factor:   43.330


  40 in total

1.  Human GDPD3 overexpression promotes liver steatosis by increasing lysophosphatidic acid production and fatty acid uptake.

Authors:  Chia-Chi C Key; Andrew C Bishop; Xianfeng Wang; Qingxia Zhao; Guan-Yuan Chen; Matthew A Quinn; Xuewei Zhu; Qibin Zhang; John S Parks
Journal:  J Lipid Res       Date:  2020-05-19       Impact factor: 5.922

2.  Dynamic changes in hepatic DNA methylation during the development of nonalcoholic fatty liver disease induced by a high-sugar diet.

Authors:  Daiane Teixeira de Oliveira; Nívia Carolina Nogueira de Paiva; Cláudia Martins Carneiro; Renata Guerra-Sá
Journal:  J Physiol Biochem       Date:  2022-06-18       Impact factor: 4.158

Review 3.  Role for animal models in understanding essential fatty acid deficiency in cystic fibrosis.

Authors:  Deanne H Hryciw; Courtney A Jackson; Nirajan Shrestha; David Parsons; Martin Donnelley; Andrew J McAinch
Journal:  Cell Mol Life Sci       Date:  2021-11-05       Impact factor: 9.261

4.  Obese mice weight loss role on nonalcoholic fatty liver disease and endoplasmic reticulum stress treated by a GLP-1 receptor agonist.

Authors:  Rayane Miranda Pontes-da-Silva; Thatiany de Souza Marinho; Luiz Eduardo de Macedo Cardoso; Carlos Alberto Mandarim-de-Lacerda; Marcia Barbosa Aguila
Journal:  Int J Obes (Lond)       Date:  2021-08-31       Impact factor: 5.095

5.  Blueberry-derived exosomes-like nanoparticles ameliorate nonalcoholic fatty liver disease by attenuating mitochondrial oxidative stress.

Authors:  Wan-Jun Zhao; Yang-Ping Bian; Qiu-Hui Wang; Fei Yin; Li Yin; Yong-Lan Zhang; Jian-Hui Liu
Journal:  Acta Pharmacol Sin       Date:  2021-05-14       Impact factor: 6.150

6.  Quantification and molecular imaging of fatty acid isomers from complex biological samples by mass spectrometry.

Authors:  Hua Zhang; Meng Xu; Xudong Shi; Yuan Liu; Zihui Li; Justin C Jagodinsky; Min Ma; Nathan V Welham; Zachary S Morris; Lingjun Li
Journal:  Chem Sci       Date:  2021-05-04       Impact factor: 9.825

7.  The Alzheimer's disease drug candidate J147 decreases blood plasma fatty acid levels via modulation of AMPK/ACC1 signaling in the liver.

Authors:  Devin Kepchia; Ling Huang; Antonio Currais; Zhibin Liang; Wolfgang Fischer; Pamela Maher
Journal:  Biomed Pharmacother       Date:  2022-01-17       Impact factor: 6.529

Review 8.  Dietary carbohydrates and fats in nonalcoholic fatty liver disease.

Authors:  Hannele Yki-Järvinen; Panu K Luukkonen; Leanne Hodson; J Bernadette Moore
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-07-13       Impact factor: 46.802

9.  Resveratrol Ameliorates High-Fat-Diet-Induced Abnormalities in Hepatic Glucose Metabolism in Mice via the AMP-Activated Protein Kinase Pathway.

Authors:  Caiping Lu; Hanying Xing; Linquan Yang; Kaiting Chen; Linyi Shu; Xiaojian Zhao; Guangyao Song
Journal:  Evid Based Complement Alternat Med       Date:  2021-06-25       Impact factor: 2.629

10.  The role of SAMM50 in non-alcoholic fatty liver disease: from genetics to mechanisms.

Authors:  Zuyin Li; Weixing Shen; Gang Wu; Changjiang Qin; Yijie Zhang; Yupeng Wang; Guohe Song; Chao Xiao; Xin Zhang; Guilong Deng; Ruitao Wang; Xiaoliang Wang
Journal:  FEBS Open Bio       Date:  2021-05-27       Impact factor: 2.693

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.